Hematologic Oncology

Amid advances in targeted therapies for patients with chronic lymphocytic leukemia (CLL), researchers also have been making strides in the realm of chemoimmunotherapy regimens for the disease.

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, gives an overview of novel therapies for the treatment of patients with acute myeloid leukemia (AML).

Founded in 1987, Gilead Sciences made a name for itself in 1996, when it launched Vistide, a treatment for cytomegalovirus retinitis in patients with AIDS.

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses individualizing the treatment of chronic lymphocytic leukemia (CLL).

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the clinical value of IPI-145 and ABT-199 as treatment options for lymphoid malignancies.

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment recommendations for patients with CLL.

Jennifer R. Brown, MD, PhD, and John Byrd, MD, are leading researchers in the emerging field of Bruton tyrosine kinase (BTK) inhibition in chronic lymphocytic leukemia (CLL) and other B-cell malignancies.

Farhad Ravandi, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance in adults with acute myeloid leukemia.

A greater understanding of the molecular mechanisms underlying lymphoid malignancies has fostered the development of targeted therapies, including those aimed at B-cell signaling pathways.

Ari Melnick, MD, professor of medicine, Weill Cornell Medical College, discusses the association between epigenetic diversity and clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL).

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the challenges of treating patients with Hodgkin's lymphoma.

Treatment with the oral PI3K-delta inhibitor idelalisib produced an overall response rate of 57% with an average response duration of 12.5 months in heavily pretreated patients with indolent non-Hodgkin's lymphoma.